- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00472641
Geodon in Weight Loss Study for Bipolar Disorders
March 29, 2017 updated by: Terrence Ketter, Stanford University
Adjunctive Ziprasidone in Overweight and Obese Patients With Bipolar Disorder
This research study is designed to determine if replacing your current antipsychotic and/or mood stabilizer with ziprasidone (Geodon) will impact weight.
This research is being conducted because Geodon has a documented effect on mood.
Additionally, we believe Geodon to be an effective medication for overweight or obese patients with bipolar disorder.
There will be approximately 25 patients enrolled in this study.
Study Overview
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:Patients will meet the following criteria to be eligible to participate in the study:
- Diagnosis of Bipolar Disorder Type I, Type II, or NOS treated in ongoing therapy with atypical antipsychotic(s) and/or mood stabilizer(s) that have been implicated in causing weight gain (i.e. lithium, valproate, olanzapine, risperidone, quetiapine, aripiprazole).
- Age 18-65 years old
- Males; or nonpregnant, nonlactating females who are postmenopausal, surgically sterilized, or using a barrier method of contraception and have a negative pregnancy test
- Initial body mass index e 30 kg/m2, or e 27 kg/m2 and demonstrating or receiving treatment for metabolic consequences of overweight (fasting total cholesterol e 200mg/dL, fasting triglycerides e 250 mg/dL, or fasting blood glucose e 100 mg/dL).
- Stable medication regimen of at least one month
- Not have been hospitalized due to medical or psychiatric reasons during the past year from date of consent.
- Ability to understand and cooperate with study procedures
- Have signed a written informed consent prior to entering the study Exclusion Criteria:Patients may not participate in the study if they have any of the following conditions:
- One of the following DSM-IV Axis I diagnoses: delirium, dementia, amnestic and other cognitive disorders, schizophrenia, anorexia nervosa or bulimia, or substance abuse or dependence (active within the last month), abuse of illicit drugs (excluding marijuana) within the past month
- Antisocial personality disorder
- Medical complications of obesity such as diabetes, hypertension, hyperlipidemia, and cardiovascular disease unless followed by their own general medical practitioner who authorizes their participation in the trial, and continues to follow them medically and make necessary adjustments of concurrent antidiabetic, antihypertensive, antihyperlipidemic agents during the trial;
- Item 10 (Suicidal Thoughts) on the MADRS greater than or equal to 4
- Suicide attempt within the past three months
- Obesity of endocrine origin
- Seizure disorders
- Progressive neurologic or systemic disorders; HIV
- Other serious illnesses such as cardiac, hepatic (including cirrhosis), renal, respiratory, neurologic, or hematologic disease or glaucoma
- Hypothyroidism or hyperthyroidism unless adequately treated with TSH no more than 10% above or below the limits of the normal range.
- Administration of any investigational drug within 30 days prior to screening
- Allergy or hypersensitivity to ziprasidone
- Administration of clozapine in the prior three months
- Pregnancy within the past six months
- Patients will be discontinued from the study should they develop any significant adverse side effects that cannot be managed by dosage adjustment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ziprasidone/Geodon
Ziprasidone/Geodon up to 320 mg per day
|
Ziprasidone/Geodon
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Primary Outcome Measure Was Weight Change From Baseline to Endpoint.
Time Frame: Baseline, 12 weeks
|
The primary outcome measure will be the change in weight from baseline to endpoint using a random regression mixed effects model.
|
Baseline, 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes From Baseline to Endpoint in Body Mass Index (BMI)
Time Frame: Baseline, 12 weeks
|
Secondary outcome measures will include the change from baseline to endpoint in Body Mass Index (BMI).
|
Baseline, 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Terence Arthur Ketter, Stanford University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (Actual)
December 1, 2009
Study Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
May 11, 2007
First Submitted That Met QC Criteria
May 11, 2007
First Posted (Estimate)
May 14, 2007
Study Record Updates
Last Update Posted (Actual)
May 9, 2017
Last Update Submitted That Met QC Criteria
March 29, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Bipolar and Related Disorders
- Bipolar Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Ziprasidone
Other Study ID Numbers
- 96972
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
University Hospital, Strasbourg, FranceUnknownBipolar Disorder I | Bipolar Disorder II | Rapid Cycling Bipolar Disorder(DSM-IV-TR)France
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoNot yet recruitingBipolar Disorder | Bipolar Depression | Treatment- Resistant Bipolar Disorder | Type 2 Bipolar DisorderCanada
Clinical Trials on Ziprasidone/Geodon
-
Donald C. Goff, MDPfizerCompletedSchizophreniaUnited States
-
Yale UniversityCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedBipolar DisorderUnited States
-
Dr. Reddy's Laboratories LimitedCompletedHealthyUnited States
-
University Hospitals Cleveland Medical CenterPfizerCompletedBipolar Disorder | Medication AdherenceUnited States
-
Massachusetts General HospitalPfizerCompletedBipolar Disorder | ManiaUnited States
-
Tufts Medical CenterPfizerCompletedDepression | Bipolar Disorder | Bipolar DepressionUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedSchizophrenia | Schizoaffective DisorderUnited States, Germany, Spain, Greece, Brazil, Turkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedBipolar DisorderUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedSchizophrenia | Bipolar Disorder